PMID- 22713691 OWN - NLM STAT- MEDLINE DCOM- 20130503 LR - 20220318 IS - 1523-6536 (Electronic) IS - 1083-8791 (Linking) VI - 18 IP - 11 DP - 2012 Nov TI - Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. PG - 1716-26 LID - S1083-8791(12)00235-2 [pii] LID - 10.1016/j.bbmt.2012.06.001 [doi] AB - Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRB1, HLA-DQB1 allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age >/=40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD. CI - Copyright (c) 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Finke, Jurgen AU - Finke J AD - Department of Hematology and Oncology, Universitatsklinikum Freiburg, Freiburg, Germany. juergen.finke@uniklinik-freiburg.de FAU - Schmoor, Claudia AU - Schmoor C FAU - Bethge, Wolfgang A AU - Bethge WA FAU - Ottinger, Hellmut D AU - Ottinger HD FAU - Stelljes, Matthias AU - Stelljes M FAU - Zander, Axel R AU - Zander AR FAU - Volin, Liisa AU - Volin L FAU - Heim, Dominik A AU - Heim DA FAU - Schwerdtfeger, Rainer AU - Schwerdtfeger R FAU - Kolbe, Karin AU - Kolbe K FAU - Mayer, Jiri AU - Mayer J FAU - Maertens, Johan A AU - Maertens JA FAU - Linkesch, Werner AU - Linkesch W FAU - Holler, Ernst AU - Holler E FAU - Koza, Vladimir AU - Koza V FAU - Bornhauser, Martin AU - Bornhauser M FAU - Einsele, Hermann AU - Einsele H FAU - Bertz, Hartmut AU - Bertz H FAU - Grishina, Olga AU - Grishina O FAU - Socie, Gerard AU - Socie G CN - ATG-Fresenius Trial Group LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20120617 PL - United States TA - Biol Blood Marrow Transplant JT - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JID - 9600628 RN - 0 (Antilymphocyte Serum) RN - 0 (HLA Antigens) RN - 0 (Myeloablative Agonists) SB - IM MH - Acute Disease MH - Adolescent MH - Adult MH - Age Factors MH - Antilymphocyte Serum/*therapeutic use MH - Chronic Disease MH - Female MH - Graft vs Host Disease/etiology/mortality/*prevention & control MH - HLA Antigens/immunology MH - Hematopoietic Stem Cell Transplantation/*adverse effects/mortality MH - Histocompatibility Testing MH - Humans MH - Male MH - Middle Aged MH - Myeloablative Agonists/*therapeutic use MH - Prospective Studies MH - Severity of Illness Index MH - Survival Rate MH - Transplantation Conditioning/*methods MH - Transplantation, Homologous MH - Unrelated Donors FIR - Finke, J IR - Finke J FIR - Schneeberger, H IR - Schneeberger H FIR - Petan, J IR - Petan J FIR - Kainz, A IR - Kainz A FIR - Schmoor, C IR - Schmoor C FIR - Grishina, O IR - Grishina O FIR - Schilling, B IR - Schilling B FIR - Kaufmann, M IR - Kaufmann M FIR - Tostmann, R IR - Tostmann R FIR - Kollmer, A IR - Kollmer A FIR - Nuss, S IR - Nuss S FIR - Wenig, C IR - Wenig C FIR - Bertz, H IR - Bertz H FIR - Egger, M IR - Egger M FIR - Zander, A R IR - Zander AR FIR - Wolschke, C IR - Wolschke C FIR - Schwerdtfeger, R IR - Schwerdtfeger R FIR - Kolbe, K IR - Kolbe K FIR - Thomas, S IR - Thomas S FIR - Ullmann, A IR - Ullmann A FIR - Schulze-Bergkamen, A IR - Schulze-Bergkamen A FIR - Hahn, J IR - Hahn J FIR - Bornhauser, M IR - Bornhauser M FIR - Schaefer-Eckart, K IR - Schaefer-Eckart K FIR - Gluckman, E IR - Gluckman E FIR - Esperou, H IR - Esperou H FIR - Robin, M IR - Robin M FIR - Michallet, M IR - Michallet M FIR - Nicolini, F IR - Nicolini F FIR - Buzyn, A IR - Buzyn A FIR - Rubio, M T IR - Rubio MT FIR - Clement, L IR - Clement L FIR - Salmon, A IR - Salmon A FIR - Feugier, P IR - Feugier P FIR - Ruutu, T IR - Ruutu T FIR - Volin, L IR - Volin L FIR - Juvonen, E IR - Juvonen E FIR - Nihtinen, A IR - Nihtinen A FIR - Remes, K IR - Remes K FIR - Putkonen, M IR - Putkonen M FIR - Voglova, J IR - Voglova J FIR - Lebavy, J IR - Lebavy J FIR - Zak, P IR - Zak P FIR - Heim, D IR - Heim D FIR - Gratwohl, A IR - Gratwohl A FIR - Passweg, J IR - Passweg J FIR - Arber, C IR - Arber C FIR - Tsakiris, A IR - Tsakiris A FIR - Linkesch, W IR - Linkesch W FIR - Reitter, S IR - Reitter S FIR - Lutz, D IR - Lutz D FIR - Maertens, A IR - Maertens A FIR - Theunissen, K IR - Theunissen K FIR - Boogaerts, M IR - Boogaerts M FIR - Verhoef, G IR - Verhoef G FIR - Rowe, J IR - Rowe J FIR - Rosenvald-Zuckermann, T IR - Rosenvald-Zuckermann T FIR - Shapira, M IR - Shapira M FIR - Resnik, I IR - Resnik I FIR - Nagler, A IR - Nagler A FIR - Shimoni, A IR - Shimoni A FIR - Yerushalmi, R IR - Yerushalmi R FIR - Sierra, J IR - Sierra J FIR - Valcarcel, D IR - Valcarcel D FIR - Astorga, M IR - Astorga M FIR - Bosi, A IR - Bosi A FIR - Borner, G IR - Borner G FIR - Gamperl, H J IR - Gamperl HJ FIR - Jauch, J IR - Jauch J FIR - Muller, Ch IR - Muller Ch FIR - Scheele, J IR - Scheele J FIR - Bethge, W A IR - Bethge WA FIR - Einsele, H IR - Einsele H FIR - Muller, R F K IR - Muller RF FIR - Hantschel, M IR - Hantschel M FIR - Ottinger, H D IR - Ottinger HD FIR - Stelljes, M IR - Stelljes M FIR - Kroger, N M IR - Kroger NM FIR - Ayuketang, F A IR - Ayuketang FA FIR - Kaltenhauser, J IR - Kaltenhauser J FIR - Stubig, T IR - Stubig T FIR - Taube, R H IR - Taube RH FIR - Holler, E IR - Holler E FIR - Kolb, H J IR - Kolb HJ FIR - Reibke, R IR - Reibke R FIR - Wandt, H IR - Wandt H FIR - Socie, G IR - Socie G FIR - Yakoub-Agha, I IR - Yakoub-Agha I FIR - Jouet, J P IR - Jouet JP FIR - Petillon, M O IR - Petillon MO FIR - Bordigoni, P IR - Bordigoni P FIR - Itala, M IR - Itala M FIR - Kauppila, M IR - Kauppila M FIR - Mayer, J IR - Mayer J FIR - Krejci, M IR - Krejci M FIR - Brychtova, Y IR - Brychtova Y FIR - Koza, V IR - Koza V FIR - Karas, M IR - Karas M FIR - Staber, P B IR - Staber PB FIR - Krieger, O IR - Krieger O FIR - Or, R IR - Or R FIR - Perez Simon, J A IR - Perez Simon JA FIR - Astorga, M IR - Astorga M FIR - Guidi, S IR - Guidi S EDAT- 2012/06/21 06:00 MHDA- 2013/05/04 06:00 CRDT- 2012/06/21 06:00 PHST- 2012/03/08 00:00 [received] PHST- 2012/06/04 00:00 [accepted] PHST- 2012/06/21 06:00 [entrez] PHST- 2012/06/21 06:00 [pubmed] PHST- 2013/05/04 06:00 [medline] AID - S1083-8791(12)00235-2 [pii] AID - 10.1016/j.bbmt.2012.06.001 [doi] PST - ppublish SO - Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17.